Isomorphic Labs, a drug discovery startup developing AI models for drug design and development, has raised £1.5 billion in Series B funding led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund. The funding will support the continued development of Isomorphic Labs’ AI drug design engine, scale the business globally and progress its therapeutic pipeline towards the clinic.
Founded in 2021, Isomorphic Labs develops foundational AI models that work across multiple therapeutic areas and drug modalities. The company’s AI drug design engine, IsoDDE, is designed to predict biological systems and support drug discovery by identifying viable drug candidates with greater speed and accuracy. Recent research published by Isomorphic Labs highlighted new capabilities intended to bridge structure prediction and real-world drug discovery.
The new funding will be used to continue developing and deploying IsoDDE, expand therapeutic programmes and hire AI, engineering, drug design and clinical talent across its global sites. Isomorphic Labs said global scale is central to its long-term aim of applying AI to complex biological and medical challenges.
Strategic partnerships with pharmaceutical groups including Novartis, Lilly and Johnson & Johnson form part of Isomorphic Labs’ commercial strategy. The collaborations are intended to validate the company’s AI-first approach to drug discovery and demonstrate its use within the pharmaceutical industry.
Demis Hassabis leads Isomorphic Labs as Founder and CEO, while Max Jaderberg serves as President. The business is headquartered in London, with additional offices in Cambridge, Massachusetts and Lausanne, Switzerland.
This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development. Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease.
This milestone is built on the strength of our AI drug design engine, which has already proven its worth across our internal programs by hitting key milestones and identifying viable candidates with unprecedented speed. Our drug design engine works, and it's giving us a repeatable way to design new medicines for a wide range of diseases, building a future of medicine that was previously out of reach.
The application of AI in healthcare offers a profound opportunity. Isomorphic Labs has already made extraordinary progress in harnessing AI to accelerate drug discovery, and we are excited by this momentum and the early promise of the technology platform. This trajectory is encouraging, and this funding will be used to accelerate the work and bring important interventions to market with greater speed.
We are humbled to have the opportunity to continue to support Isomorphic's mission to solve all disease. Over the past year, our conviction in the team has only deepened as they've made significant progress in building a unified AI drug design engine to define a new age of drug discovery and design.
